Close Menu

Editor's Pick

The FDA has been prodding labs performing pharmacogenetic testing, and software firms providing reports from such testing, to undergo regulatory review.

The rise of new protein analysis techniques have some questioning whether mass spec will in coming years retain its dominant position within proteomics.

The multi-omics analytics company is assisting drug discovery and precision medicine as the first partner of Mayo's Clinical Data Analytics Platform.

The firm has opened a $10 million Series A financing round that it expects to close in late summer to support running clinical studies for its assay.

Mere weeks after the 2019-nCoV sequence was released, firms, agencies, and research groups have already created PCR-based tests.

The 2010s saw major strides made through several large-scale initiatives aimed at mapping the human proteome and developing approaches for clinical work.

Researchers have identified immune cell gene expression signatures that could one day be developed into tests to predict response to treatment.

Researchers' picks range from emerging tools like deep learning to fundamental issues like false discovery rates and infrastructure for mass spec data sharing.

Ongoing Scripps research into polygenic risk for coronary artery disease now offers remote genetic counseling as well as an Android app.

Highlights included mass spec-focused developments like data-independent acquisition and ion mobility along with platforms including Thermo Fisher's Q Exactive.

Pages

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.